MA40620A - Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression - Google Patents

Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression

Info

Publication number
MA40620A
MA40620A MA040620A MA40620A MA40620A MA 40620 A MA40620 A MA 40620A MA 040620 A MA040620 A MA 040620A MA 40620 A MA40620 A MA 40620A MA 40620 A MA40620 A MA 40620A
Authority
MA
Morocco
Prior art keywords
treatment
depression
methods
val66met
snp
Prior art date
Application number
MA040620A
Other languages
English (en)
Inventor
Lodewijk Ivo Caers
Giacomo Salvadore
Jaskaran Singh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40620(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40620A publication Critical patent/MA40620A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes et des régimes posologiques pour le traitement de la dépression (de préférence, une dépression résistante aux traitements), pour le traitement de la dépression chez un patient suicidaire, et/ou pour le traitement et/ou la prévention d'une tendance suicidaire (par exemple des idéations suicidaires) consistant à réaliser le génotypage d'un patient afin de déterminer son polymorphisme val66met rs6265 dans le bdnf et à lui administrer une kétamine, de préférence une
MA040620A 2014-09-15 2015-09-14 Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression MA40620A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462050439P 2014-09-15 2014-09-15

Publications (1)

Publication Number Publication Date
MA40620A true MA40620A (fr) 2016-03-24

Family

ID=54200096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040620A MA40620A (fr) 2014-09-15 2015-09-14 Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression

Country Status (11)

Country Link
US (6) US20160074340A1 (fr)
EP (2) EP3193853A1 (fr)
JP (2) JP2017528483A (fr)
KR (1) KR20170054470A (fr)
CN (1) CN107208133A (fr)
AU (1) AU2015318123A1 (fr)
CA (1) CA2961208A1 (fr)
IL (2) IL251068A0 (fr)
MA (1) MA40620A (fr)
MX (1) MX2017003366A (fr)
WO (1) WO2016044150A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
EP3193853A1 (fr) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017161289A1 (fr) * 2016-03-18 2017-09-21 Takeda Pharmaceutical Company Limited Procédé d'identification de répondeurs d'essai clinique dans un groupe placebo en dépression majeure
WO2018079693A1 (fr) * 2016-10-27 2018-05-03 国立大学法人 千葉大学 Applications pharmaceutiques de la (s)-norkétamine et de ses sels
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
SG11202005896WA (en) * 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
CA3103440A1 (fr) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Procede de traitement d'un trouble depressif majeur
WO2020070706A1 (fr) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Régime posologique d'eskétamine pour le traitement d'un trouble dépressif majeur
WO2020075134A1 (fr) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Eskétamine pour une utilisation dans le traitement d'un trouble dépressif majeur
EP3934632A4 (fr) * 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de la dépression
KR20220045929A (ko) * 2019-04-09 2022-04-13 비스타젠 쎄라퓨틱스, 인크. 신경 질환의 치료 반응과 관련된 유전적 변이
EP3923920A4 (fr) * 2019-08-05 2022-11-23 The Ketamine Research Foundation Kétamine pour le traitement de symptômes et de troubles post-partum
EP4021432A4 (fr) 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de patients présentant un trouble dépressif majeur, notamment la suicidalité
KR102312387B1 (ko) * 2019-11-15 2021-10-13 이화여자대학교 산학협력단 인지 증강을 위한 개인 맞춤형 경두개 직류 자극 프로토콜 생성 방법 및 장치
WO2021137147A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
PH12022551856A1 (en) * 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
US20220175701A1 (en) * 2020-12-08 2022-06-09 Therapeutic Solutions International, Inc. Treatment of major depressive disorder and suicidal ideations through stimulation of hippocampal neurogenesis utilizing plant-based approaches
JP2024511169A (ja) * 2021-03-26 2024-03-12 ピーエックス・アイエヌジー，エルエルシー 運動誘発性精神疲労を低減するためのパラキサンチンの使用
EP4494634A4 (fr) * 2022-04-26 2025-07-23 Yichang Humanwell Pharmaceutical Co Ltd Préparation liquide d'eskétamine et son utilisation
CN115418398B (zh) * 2022-08-30 2025-02-18 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用
JP2026501567A (ja) * 2022-12-28 2026-01-16 パーセプション ニューロサイエンス，インコーポレイティド Ｒ－ケタミンの投与方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
USD308100S (en) 1987-08-28 1990-05-22 Schering Corporation Nasal spray pump
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DK0814790T3 (da) 1995-02-24 2003-11-10 Stuart L Weg Indgivelse af ketamin med henblik på afgiftning
WO1997007750A1 (fr) 1995-08-30 1997-03-06 Weg Stuart L Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
USD401323S (en) 1996-01-23 1998-11-17 Ing. Erich Pfeiffer Gmbh Medication dispensing apparatus
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
AU135762S (en) 1998-01-09 1998-11-19 Astrazeneca Ab Sprayer
USD433123S (en) 1998-07-09 2000-10-31 Zeneca Limited Nasal spray
CA2338457C (fr) 1998-07-24 2009-11-17 Seo Hong Yoo Preparation de dosages de solution claire aqueuse avec des acides biliaires
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (fr) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
USD471973S1 (en) 2001-08-08 2003-03-18 N.V. Organon Applicator for a nasal delivery device
EP1551393A4 (fr) 2002-07-30 2010-06-16 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
USD544957S1 (en) 2005-03-23 2007-06-19 Rexam Dispensing Systems Nasal spray dispenser
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
CA111438S (fr) 2005-05-23 2006-12-22 Rexam Dispensing Sys Pulvérisateur nasal
EP2526987A3 (fr) 2005-06-01 2013-04-24 SHL Group AB Dispositif pour administrer un médicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20070256688A1 (en) 2006-04-21 2007-11-08 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
EP2029136A4 (fr) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc Traitement pour troubles dépressifs
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20100095957A1 (en) 2007-03-02 2010-04-22 Corbco, Inc. Manually operated monodose nasal sprayer device
WO2008151179A2 (fr) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Phénéthylamines substituées
WO2009131794A1 (fr) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Combinaisons de co-médicament opioïdekétamine et norkétamine dans la gestion de la douleur
USD610253S1 (en) 2009-03-31 2010-02-16 Daikyo Seiko, Ltd. Pre-filled nasal drip device
USD610678S1 (en) 2009-03-31 2010-02-23 Daikyo Seiko, Ltd. Syringe plunger and proximal end of a syringe barrel for a pre-filled nasal drip device
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
USD699342S1 (en) 2011-03-09 2014-02-11 Suzuken Company Limited Injector
WO2013003669A2 (fr) 2011-06-30 2013-01-03 University Of South Florida Compositions, méthodes d'utilisation et méthodes de traitement
USD697201S1 (en) 2011-07-01 2014-01-07 R5 Pharmaceuticals Limited Buccal delivery device adaptor
US20130056557A1 (en) 2011-09-02 2013-03-07 Maggie Blair Felder Non-pressurized flavored liquid oxygen breath spray device
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
CN104053785A (zh) 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2013138322A1 (fr) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
MX2015002378A (es) 2012-08-23 2015-09-25 Stuart L Weg Composicion ansiolitica, formulacion y metodo de uso.
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
US20140263456A1 (en) 2013-03-15 2014-09-18 Launce R. Barber Child-resistant closure systems for containers
US20140263457A1 (en) 2013-03-15 2014-09-18 Launce R. Barber Child-resistant closure systems for containers
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (fr) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Compositions et préparations combinées pour le traitement des douleurs oropharyngées
CA2936809A1 (fr) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprenant de la ketamine pour le traitement d'un trouble du spectre de l'autisme
EP3272338B1 (fr) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Forme posologique orale de kétamine
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3193853A1 (fr) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
WO2016109427A1 (fr) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Procédé de maintien de l'effet antidépresseur de la kétamine avec du lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression

Also Published As

Publication number Publication date
MX2017003366A (es) 2018-02-01
EP3193853A1 (fr) 2017-07-26
JP2021054829A (ja) 2021-04-08
IL251068A0 (en) 2017-04-30
EP3725307A1 (fr) 2020-10-21
CN107208133A (zh) 2017-09-26
US11173134B2 (en) 2021-11-16
WO2016044150A1 (fr) 2016-03-24
IL279119A (en) 2021-01-31
US11311500B2 (en) 2022-04-26
US20250255835A1 (en) 2025-08-14
US20210106545A1 (en) 2021-04-15
JP2017528483A (ja) 2017-09-28
US20160074340A1 (en) 2016-03-17
US20230089113A1 (en) 2023-03-23
US10869844B2 (en) 2020-12-22
US20210308076A1 (en) 2021-10-07
AU2015318123A1 (en) 2017-03-30
KR20170054470A (ko) 2017-05-17
CA2961208A1 (fr) 2016-03-24
US20200246279A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IL279119A (en) VAL66MET genotype-specific dosage regimens (SNP rs6265) and methods for treating depression
PH12017502103A1 (en) Methods and kits for treating depression
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EA201790737A1 (ru) Комбинированная терапия
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201790785A1 (ru) Производные тетрагидроизохинолина
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3326559A4 (fr) Instrument de traitement aux ultrasons, et ensemble de traitement aux ultrasons
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
MX377714B (es) Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
EA201691582A1 (ru) Новые фармацевтические препараты
BR112016023948A2 (pt) proteínas fc multiméricas
EA201790802A1 (ru) Соединения против tnf
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201691314A1 (ru) Терапевтические способы и композиции
EP2934403A4 (fr) Timbre pour le traitement de maladies des paupières contenant du clobétasol
EA201692534A1 (ru) Способы лечения гипотонии
MX356412B (es) Anticuerpos anti-kdr y metodos de uso.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза